Tags

Type your tag names separated by a space and hit enter

Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
Expert Rev Neurother. 2009 Dec; 9(12):1781-9.ER

Abstract

Parkinson's disease is a progressive, neurodegenerative disorder affecting millions of people worldwide. Given the aging population, the prevalence of the disease is expected to increase substantially. The mainstay of treatment has been dopamine replacement therapy with carbidopa, levodopa, dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors and amantadine. Nonmotor features, such as cognitive impairment, mood disorders, autonomic dysfunction, gastrointestinal and genitourinary dysfunction, have a substantial impact on Parkinson's disease patients and their quality of life. This review will provide an overview on medications currently available for management of both motor and nonmotor symptoms of Parkinson's disease. Focus will be placed on recent and evolving studies evaluating symptomatic and neuroprotective effects of medications, and how such studies may impact the future management of Parkinson's disease.

Authors+Show Affiliations

Neurological Institute at Columbia University Medical Center, 710 W168th St, 3rd floor, New York, NY 10032, USA. nd2284@mail.cumc.columbia.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19951137

Citation

Diaz, Nancy L., and Cheryl H. Waters. "Current Strategies in the Treatment of Parkinson's Disease and a Personalized Approach to Management." Expert Review of Neurotherapeutics, vol. 9, no. 12, 2009, pp. 1781-9.
Diaz NL, Waters CH. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Rev Neurother. 2009;9(12):1781-9.
Diaz, N. L., & Waters, C. H. (2009). Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Review of Neurotherapeutics, 9(12), 1781-9. https://doi.org/10.1586/ern.09.117
Diaz NL, Waters CH. Current Strategies in the Treatment of Parkinson's Disease and a Personalized Approach to Management. Expert Rev Neurother. 2009;9(12):1781-9. PubMed PMID: 19951137.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current strategies in the treatment of Parkinson's disease and a personalized approach to management. AU - Diaz,Nancy L, AU - Waters,Cheryl H, PY - 2009/12/3/entrez PY - 2009/12/3/pubmed PY - 2010/2/20/medline SP - 1781 EP - 9 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 9 IS - 12 N2 - Parkinson's disease is a progressive, neurodegenerative disorder affecting millions of people worldwide. Given the aging population, the prevalence of the disease is expected to increase substantially. The mainstay of treatment has been dopamine replacement therapy with carbidopa, levodopa, dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors and amantadine. Nonmotor features, such as cognitive impairment, mood disorders, autonomic dysfunction, gastrointestinal and genitourinary dysfunction, have a substantial impact on Parkinson's disease patients and their quality of life. This review will provide an overview on medications currently available for management of both motor and nonmotor symptoms of Parkinson's disease. Focus will be placed on recent and evolving studies evaluating symptomatic and neuroprotective effects of medications, and how such studies may impact the future management of Parkinson's disease. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/19951137/Current_strategies_in_the_treatment_of_Parkinson's_disease_and_a_personalized_approach_to_management_ L2 - https://www.tandfonline.com/doi/full/10.1586/ern.09.117 DB - PRIME DP - Unbound Medicine ER -